Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses
| Autor: | Eun Kyoung Kim, Sung-Bae Kim, Shin Kim, Soon Jong Lee, Michael W. Kim, Sanghee Kim, Sung-Soo Yoon, Jung Sin Lee, Yoon Shin Lee, Hyo Jung Kim, Cheolwon Suh, Ki-Hyun Kim |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Neutrophil Engraftment Randomization business.industry Immunology Hematology medicine.disease law.invention Granulocyte colony-stimulating factor Surgery Transplantation Lenograstim Autologous stem-cell transplantation Randomized controlled trial law Anesthesia medicine Immunology and Allergy business Multiple myeloma |
| Zdroj: | Transfusion. 44:533-538 |
| ISSN: | 0041-1132 |
| Popis: | Background G-CSF is used to enhance hematopoietic recovery after autologous stem cell transplantation (ASCT), but the optimal dose of G-CSF during engraftment has not been established. The medical cost of ASCT is a serious financial burden in developing countries, and G-CSF is the most costly drug used in this procedure. We evaluated whether a lower, vial-size fitted dose of lenograstim is clinically equivalent to a higher fixed dose. Study design and methods A prospective randomized study was performed on 33 patients (11 non-Hodgkin's lymphoma, 8 multiple myeloma, 14 breast cancer) undergoing ASCT. Patients were randomly administered 100 micro g or 250 micro g lenograstim daily starting on the next day of ASCT, with a minimum infusion of 3 x 10(6) CD34+ cells per kg. Results For both lenograstim doses, median time to neutrophil engraftment was 9 days and median time to PLT engraftment was 11 days. Episodes of clinically documented infections were 10 per 379 patient-days in the 100 microg per day group and 10 per 320 patient-days in the 250 microg per day group. There were no between-group differences in requirements for transfusion of RBCs or PLTs. Duration of hospitalization was 16 days for the 100 microg per day group and 17 days for the 250 microg per day group. Daily lenograstim dose per patient's body weight and total amount of lenograstim used during ASCT were both significantly lower in the 100 microg per day group. Conclusion Administration of 100 microg per day of lenograstim showed comparable clinical efficacy to 250 microg per day lenograstim for immediate hematopoietic recovery after ASCT. Use of the lower dose was associated with lower overall lenograstim usage and lower cost. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text